The two companies – Cogniant.co and Mediktor – were chosen from a group of over 220 submissions to BTA’s Spring 2020 Call for Innovator Applications. They were selected based upon having developed highly promising broad and long-term digital solutions to healthcare gaps, brought to light by the global COVID-19 pandemic. As participants in this cohort of exceptional BTA innovators, HITLAB will be leading efforts to rapidly verify their solutions for measurable outcomes, market-fit and/or potential impact.

This work has support and guidance from the BTA’s Board Members – a consortium of executive leaders from across life science, pharmaceutical, academic medical institutions and healthcare providers (including New York City Economic Development Corporation, Merck Global Health Innovation Fund LLC, BDO, Medidata Solutions, Atlas Venture, StartUp Health, Novartis Biome, CATALAIZE, Consummate Capital, and Northwell Health) – all committed to improving health outcomes and care delivery through verified emerging technologies.

During this pandemic, various disparities in healthcare has become more evident than ever before. In order for appropriate treatments to be even more accessible for those that need it most, they must be compact, easily deployed, and highly cost effective. By identifying promising early stage innovations which can streamline health delivery processes and improve patient outcomes, the HITLAB Breakthrough Alliance is working to reduce healthcare disparities. Though objective testing and value verification, BTA hopes to fast-track proven solutions toward broad diffusion into health systems around the globe.